BioCentury on BioBusiness,
Next steps in obesity after FDA approval of Belviq lorcaserin from Arena, Eisai
Related tables, figures and sidebars
Belviq breaks through
Monday, July 9, 2012
Pharmaceuticals Inc. and partner Eisai
Pharmaceuticals Co. Ltd. will have a fine line to walk as they market
Belviq lorcaserin for obesity. They want to improve patient compliance, which
historically has not been good in obesity, while also preventing the key thing
doctors believe could make Belviq a blockbuster - combining it with the generic
On June 27, FDA approved
Belviq in combination with diet and exercise for chronic weight management in
adults with a BMI >=30 kg/m2 or in adult
patients with a BMI >=27 kg/m2 with at least
one co-morbid indication.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]